NCT04809454

Brief Summary

Thyroxin a vital hormone for life lot of body functions depend on proper functioning on pituitary thyroid axis. it exists in two major forms Thyroxine (T4) and (T3) , each of them containing two iodine atoms on their inner (tyrosine) ring. Synthesis of reasonable quantities of thyroid hormones requires adequate iodine intake to allow sufficient thyroidal uptake. The World Health Organization (WHO) recommendation for daily intake of iodine is 150 μg for children ≥12 years and adults, and 250 μg for pregnant and lactating women. However as we know optimum amount of iodine is required for normal pituitary thyroid axis like wise excessive intake may cause over functioning of axis hence over production of hormone that can be manifested both clinically and biochemically. This study is designed to observe the frequency of over hyperthyroidism in patients taking iodinated salt.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Oct 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 16, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

March 22, 2021

Completed
6 months until next milestone

Study Start

First participant enrolled

October 1, 2021

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2022

Completed
Last Updated

September 22, 2021

Status Verified

September 1, 2021

Enrollment Period

5 months

First QC Date

March 16, 2021

Last Update Submit

September 21, 2021

Conditions

Keywords

ThyroidIodine

Outcome Measures

Primary Outcomes (1)

  • Affect of Iodinated Salt on Thyroid Status

    Affect of Iodinated Salt on Thyroid Status

    through study completion an average of 12 weeks

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

All patients presenting with biochemical hyperthythyroidism and taking Iodinated salt with age range of 18-60 years

You may qualify if:

  • All patients presenting with biochemical hyperthyroidism
  • Who are taking Iodinated salt.
  • Treatment naïve patients
  • Both genders included
  • All patients who can give consent (18-60 years)

You may not qualify if:

  • \) Pregnant females 2) Lactating mothers

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Mehwish Iftikhar

Lahore, Punjab Province, 54000, Pakistan

Location

MeSH Terms

Conditions

Thyroid Diseases

Condition Hierarchy (Ancestors)

Endocrine System Diseases

Central Study Contacts

Mehwish Iftikhar, FCPS Endocrinologyy

CONTACT

Amna Rizvi, FCPS Endocrinology

CONTACT

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

March 16, 2021

First Posted

March 22, 2021

Study Start

October 1, 2021

Primary Completion

March 1, 2022

Study Completion

March 1, 2022

Last Updated

September 22, 2021

Record last verified: 2021-09

Locations